Clinical Trial Update: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating the mechanism of action of NNC0109-0012, an anti-IL-20 monoclonal antibody, in rheumatoid arthritis patients with inadequate respo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• NNC0109-0012 (anti-IL-20 monoclonal antibody)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Inflammation, Rheumatoid Arthritis | Phase 2 | Status: WITHDRAWN